Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
INO 
Inovio Pharmaceuticals Inc (INO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: INO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.47
1 Year Target Price $7.47
| 2 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.56% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 134.98M USD | Price to earnings Ratio - | 1Y Target Price 7.47 |
Price to earnings Ratio - | 1Y Target Price 7.47 | ||
Volume (30-day avg) 5 | Beta 1.66 | 52 Weeks Range 1.30 - 5.83 | Updated Date 10/15/2025 |
52 Weeks Range 1.30 - 5.83 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -52568.65% |
Management Effectiveness
Return on Assets (TTM) -59.3% | Return on Equity (TTM) -140.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 93839714 | Price to Sales(TTM) 740.29 |
Enterprise Value 93839714 | Price to Sales(TTM) 740.29 | ||
Enterprise Value to Revenue 514.65 | Enterprise Value to EBITDA -1.09 | Shares Outstanding 53142661 | Shares Floating 52855691 |
Shares Outstanding 53142661 | Shares Floating 52855691 | ||
Percent Insiders 0.51 | Percent Institutions 19 |
Upturn AI SWOT
Inovio Pharmaceuticals Inc
Company Overview
History and Background
Inovio Pharmaceuticals Inc. was founded in 1979 as Genetronics Biomedical Corporation, later changing its name to Inovio in 2009. The company focuses on developing DNA medicines to treat and prevent cancers and infectious diseases. Significant milestones include the development of its CELLECTRA delivery system and various clinical trials for its DNA vaccine candidates.
Core Business Areas
- DNA Medicines Platform: Inovio develops DNA medicines using its proprietary CELLECTRA delivery system. These medicines target specific diseases by delivering optimized DNA plasmids directly into cells.
- Cancer Immunotherapy: Inovio is developing DNA-based immunotherapies for various cancers, aiming to stimulate the body's immune system to fight tumors.
- Infectious Diseases: Inovio develops DNA vaccines for infectious diseases, including COVID-19, Zika, and Ebola, aiming to prevent or treat these infections.
Leadership and Structure
Dr. Joseph Kim is the President and CEO. The company has a board of directors overseeing the strategic direction and management team.
Top Products and Market Share
Key Offerings
- VGX-3100 (Cervical Dysplasia): VGX-3100 is Inovio's lead product candidate, a DNA medicine for the treatment of HPV-related cervical dysplasia. Currently it is not on the market. Competitors include surgical treatments and other therapies offered by companies like Merck (Keytruda in combination) and Roche.
- INO-4800 (COVID-19 Vaccine): INO-4800 was a DNA vaccine candidate for COVID-19. Development was discontinued. Competitors included Pfizer/BioNTech (BNTX), Moderna (MRNA) and Johnson & Johnson (JNJ).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. The DNA medicine sector is relatively new but offers potential advantages in terms of speed of development and manufacturing scalability.
Positioning
Inovio is positioned as a leader in the development of DNA medicines. Its CELLECTRA delivery system is a key competitive advantage. However, the company faces challenges in clinical development and commercialization.
Total Addressable Market (TAM)
The TAM for DNA medicines is estimated to be in the billions of dollars, depending on the specific disease targets. Inovio is targeting various segments of this market, including cancer and infectious diseases, but currently has no approved products.
Upturn SWOT Analysis
Strengths
- Proprietary CELLECTRA delivery system
- Experienced management team
- Diverse pipeline of DNA medicine candidates
- Potential for rapid vaccine development
Weaknesses
- No approved products
- High cash burn rate
- Reliance on clinical trial success
- Past clinical trial setbacks
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of DNA medicine platform to new diseases
- Regulatory approvals for lead product candidates
- Government funding for vaccine development
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Funding constraints
Competitors and Market Share
Key Competitors
- MRNA
- PFE
- BNTX
Competitive Landscape
Inovio competes with established pharmaceutical companies and other biotechnology firms. Its competitive advantage lies in its DNA medicine platform and CELLECTRA delivery system. However, it faces challenges in clinical development and commercialization compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Inovio's growth has been primarily driven by its pipeline development. The stock price experienced surges during the COVID-19 pandemic but later declined.
Future Projections: Future growth depends on regulatory approvals for its lead product candidates and partnerships. Analyst estimates are highly variable due to the inherent risks in pharmaceutical development.
Recent Initiatives: Focus on VGX-3100 development and potential partnerships for commercialization.
Summary
Inovio Pharmaceuticals is a high-risk, high-reward biotechnology company. It focuses on novel DNA medicines, and their potential is counterbalanced by its high cash burn rate, lack of approved products, and history of volatile stock performance. Success hinges on the successful completion of clinical trials and regulatory approvals, and it should secure partnerships to support commercialization. Investors should be wary of the risks and potential for clinical failures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The pharmaceutical industry is subject to significant risks, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inovio Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Plymouth Meeting, PA, United States | ||
IPO Launch date 1998-02-12 | CEO, President & Director Dr. Jacqueline E. Shea Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 134 | Website https://www.inovio.com |
Full time employees 134 | Website https://www.inovio.com | ||
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.